Apnimed Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Public

  • Employees
  • 65

Employees

  • Stock Symbol
  • APMD

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $16.09
  • (As of Friday Closing)

Apnimed General Information

Description

Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).

Contact Information

Website
www.apnimed.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 39 John F. Kennedy Street
  • 4th Floor
  • Cambridge, MA 02138
  • United States
+1 (877)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 39 John F. Kennedy Street
  • 4th Floor
  • Cambridge, MA 02138
  • United States
+1 (877)

Apnimed Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Apnimed Stock Performance

As of 20-Nov-2026, Apnimed’s stock price is $16.09. Its current market cap is $670M with 41.6M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$16.09 $17.23 $13.88 - $35.29 $670M 41.6M 456K $35.88

Apnimed Financials Summary

As of 31-Mar-2026, Apnimed has a trailing 12-month revenue of $120M.

In Thousands,
USD
TTM 31-Mar-2026 FY 2026 31-Mar-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024
Revenue 120,000 120,000 38,467 8,012
EBITDA (2,317) (114,211)
Net Income (932) (111,305)
Total Assets 72,873 109,223
Total Debt 41,519 1,095
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Apnimed Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Apnimed‘s full profile, request access.

Request a free trial

Apnimed Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Apnimed‘s full profile, request access.

Request a free trial

Apnimed Patents

Apnimed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024379175-A1 Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent Pending 17-Nov-2023
EP-4808533-A1 Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent Pending 17-Nov-2023
WO-2025106773-A1 Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent Inactive 17-Nov-2023
WO-2024220343-A1 Combination of a norepinephrine reuptake inhibitor and a melatonin receptor agonist for use in treating sleep apnea Inactive 18-Apr-2023
AU-2023335927-A1 Methods and compositions for treating sleep apnea Pending 02-Sep-2022 A61K31/4725
To view Apnimed’s complete patent history, request access »

Apnimed Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Apnimed Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Apnimed‘s full profile, request access.

Request a free trial

Apnimed Investments (2)

Apnimed’s most recent deal was a Corporate Asset Purchase with Desitin Arzneimittel (Global Rights to Patents Covering Sulthiame). The deal was made on 23-Apr-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Desitin Arzneimittel (Global Rights to Patents Covering Sulthiame) 23-Apr-2025 Corporate Asset Purchase Buildings and Property
Shionogi-Apnimed Sleep Science 31-Oct-2023 Joint Venture Drug Discovery
To view Apnimed’s complete investments history, request access »

Apnimed FAQs

  • When was Apnimed founded?

    Apnimed was founded in 2017.

  • Where is Apnimed headquartered?

    Apnimed is headquartered in Cambridge, MA.

  • What is the size of Apnimed?

    Apnimed has 65 total employees.

  • What industry is Apnimed in?

    Apnimed’s primary industry is Drug Discovery.

  • Is Apnimed a private or public company?

    Apnimed is a Public company.

  • What is Apnimed’s stock symbol?

    The ticker symbol for Apnimed is APMD.

  • What is the current stock price of Apnimed?

    As of 20-Nov-2026 the stock price of Apnimed is $16.09.

  • What is the current market cap of Apnimed?

    The current market capitalization of Apnimed is $670M.

  • What is Apnimed’s current revenue?

    The trailing twelve month revenue for Apnimed is $120M.

  • What is Apnimed’s annual earnings per share (EPS)?

    Apnimed’s EPS for 12 months was $35.88.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process